Pharming Group N.V.: Revision history

20 August 2022

• curprev 13:2213:22, 20 August 2022 95.149.241.133 talk 1,129 bytes +11 No edit summary undo

13 August 2022

• curprev 20:0520:05, 13 August 2022 109.180.50.163 talk 1,118 bytes +15 No edit summary undo

7 August 2022

• curprev 13:0613:06, 7 August 2022 >Paris 1,103 bytes +1,103 Created page with "Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute k..."